PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.14 (-0.44%)

Growth Price

Overvalued by 9.60%

Stability Price

Overvalued by 62.33%

Company Metrics

  • P/E 22.59
  • P/S 4.09
  • P/B 2.95
  • EPS 1.41
  • Cash ROIC 12.30%
  • Cash Ratio 1.67
  • Dividend 1.12 / 3.48%
  • Avg. Vol. 24.15M
  • Shares 6.17B
  • Market Cap. 196.31B

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Pfizer Inc. Commences Exchange Offers for Hospira Notes
MarketWatch - 8 hours ago
NEW YORK, Sep 03, 2015 (BUSINESS WIRE) -- Pfizer Inc. ("Pfizer") PFE, -0.25% announced today that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. ("Hospira"), our ...
Pfizer (PFE) Stock Gains After Closing Hospira Acquisition -
Why Pfizer Inc. Should Feel Threatened By Roche Holding Ltd. (ADR)
Bidness ETC - Sep 1, 2015
In fiscal year 2011 (FY11), its revenues fell by 2.7% year-over-year (YoY), followed by an even higher decline of 16.2% in FY12. The company expects to be on track towards revenue growth again from 2016. Pfizer anticipates revenue gains of 12.8% YoY in ...
Pfizer Inc. (PFE) Closes 0.25% Down on the Day for September 03 - 8 hours ago
Dow Jones component Pfizer Inc. (PFE) saw its stock move -0.25% to $31.89, representing a per-share move of $0.08, on volume of 20.58 million shares for Thursday.
Pfizer (PFE) Flagged As Today's Pre-Market Laggard - Sep 1, 2015
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The stock currently has a dividend yield of 3.4%.
Large Inflow of Money Witnessed in Pfizer, Inc. - Money Flow Index
Pfizer, Inc. (NYSE:PFE) Given PT Range of $34-$48 - Markets Daily
Pfizer Inc. Sells Off 4 Drugs To Alvogen: A Smart Decision?
Bidness ETC - Aug 28, 2015
Pfizer is focusing on the long-term benefits that would result from the Hospira purchase, as the company seeks to retain its status as the world's largest drug-maker.
Pfizer says Hospira purchase will close in early September - Beloit Daily News
Worth Watching Stocks - Pfizer Inc. (NYSE:PFE), QUALCOMM Incorporated (NASDAQ ...
wsnewspublishers - 18 hours ago
The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. recently declared the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS.
Shares of Pfizer, Inc. (NYSE:PFE) Sees Large Outflow of Money
Insider Trading Report - 22 hours ago
Pfizer, Inc. (NYSE:PFE) managed to eke out gains of 0.67% in intraday trade. The share price increased by 0.21 points to $31.57.
Closing Bell Reports: Intel Corporation (INTC), Pfizer Inc. (PFE ... - WallStreet Scope
Drug Manufacturers Of Interest - Johnson & Johnson (NYSE:JNJ), Novartis AG ... - Wall Street Observer
5 Things Pfizer inc. Wants You to Know
Motley Fool - Aug 13, 2015
Pfizer (NYSE: PFE ) , arguably the preeminent name among Big Pharma companies, reported its second-quarter results roughly two weeks ago and handily surpassed Wall Street's expectations for a change.
Investor's Watch List - Pfizer Inc. (NYSE:PFE) Gilead Sciences Inc. (NASDAQ ...
wsnewspublishers - Sep 2, 2015
A federal judge said Tuesday he has an “inclination” to deny Pfizer Inc.'s four-year-old request to throw out a Justice Department lawsuit accusing the drug maker's Wyeth unit of overcharging government Medicaid health programs for the heartburn drug ...
Pfizer Inc. To Complete Hospira, Inc. Acquisition Next Month
Bidness ETC - Aug 25, 2015
Pfizer Inc. (NYSE:PFE) recently announced that U.S. regulators have approved its $16 billion acquisition deal for Hospira Inc. (NYSE:HSP) to be closed by next month.
Pfizer Gets US Approval to Acquire Hospira - Wall Street Journal